Biohacking Boom: RFK Jr Pushes FDA Peptide Deregulation as NAD Market Soars to 12B
Failed to add items
Sorry, we are unable to add the item because your shopping cart is already at capacity.
Add to basket failed.
Please try again later
Add to Wish List failed.
Please try again later
Remove from Wish List failed.
Please try again later
Follow podcast failed
Unfollow podcast failed
-
Narrated by:
-
By:
About this listen
No major deals, partnerships, or product launches emerged, though scrutiny persists on 2026 nootropic The Brain Song amid mixed reviews on efficacy and safety since its February debut.[1] The FDA's recent reversal on NMN—now lawful as a dietary supplement after industry petitions—marks a key win, enabling broader marketing.[2] Verified stats show the global NAD-support market, central to biohacking longevity, hit 3.45 billion dollars in 2024 and is forecast to reach 12.18 billion by 2033, driven by demand for cellular energy and anti-aging.[2]
Consumer behavior shifts toward self-optimization, with more bypassing regulations for gray-market peptides, differing from prior months' wearable focus.[1] No price changes or supply disruptions appear, but leaders like Kennedy champion medical libertarianism, favoring choice over 2025's strict enforcement.[1]
Compared to recent reporting, this period hums with advocacy momentum absent blockbuster disruptions, priming volatility if peptide rules ease.[1] Overall, biohacking edges mainstream via policy tailwinds and longevity hype.
For great deals today, check out https://amzn.to/44ci4hQ
This content was created in partnership and with the help of Artificial Intelligence AI
No reviews yet
In the spirit of reconciliation, Audible acknowledges the Traditional Custodians of country throughout Australia and their connections to land, sea and community. We pay our respect to their elders past and present and extend that respect to all Aboriginal and Torres Strait Islander peoples today.